Related Experiment Video
Updated: May 19, 2026
07:29
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Emerging developments of chemoradiotherapy in stage III NSCLC
1Edinburgh Cancer Centre, NHS Lothian and University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK. aprice@staffmail.ed.ac.uk
Nature Reviews. Clinical Oncology
|August 29, 2012
Summary
Standard stage III non-small cell lung cancer (NSCLC) treatment is chemoradiotherapy. However, many patients cannot tolerate this, necessitating faster clinical trial research for improved outcomes.
Area of Science:
- Oncology
- Radiotherapy
- Medical Oncology
Background:
- Concomitant chemotherapy and radiotherapy is the standard treatment for stage III non-small-cell lung cancer (NSCLC).
- Many NSCLC patients are elderly or have comorbidities, precluding aggressive treatment.
- Existing research focuses on dose escalation, novel chemotherapy, biological agents, vaccines, and technical radiotherapy modifications.
Approach:
- Investigating radiotherapy dose escalation.
- Exploring new chemotherapy combinations.
- Evaluating biological agents and cancer vaccines.
- Assessing technical radiotherapy modifications like intensity-modulated radiotherapy and particle beam therapy.
Key Points:
- Phase III trials for new NSCLC treatments are lengthy and insufficient for rapid advancement.
- Improving clinical trial accrual is crucial for accelerating research.
- Potential improvements include changes in research governance, cooperative group activity, trial design, and patient consent.
Conclusions:
- Accelerating NSCLC research requires innovative approaches to clinical trial design and execution.
- Enhancing clinical trial accrual is paramount to improving patient outcomes in a timely manner.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...